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Abstract
Background: The factors influencing variation in the clinical forms of Chagas disease have not been elucidated; however, it
is likely that the genetics of both the host and the parasite are involved. Several studies have attempted to correlate the T.
cruzi strains involved in infection with the clinical forms of the disease by using hemoculture and/or PCR-based genotyping
of parasites from infected human tissues. However, both techniques have limitations that hamper the analysis of large
numbers of samples. The goal of this work was to identify conserved and polymorphic linear B-cell epitopes of T. cruzi that
could be used for serodiagnosis and serotyping of Chagas disease using ELISA.
Methodology: By performing B-cell epitope prediction on proteins derived from pair of alleles of the hybrid CL Brener
genome, we have identified conserved and polymorphic epitopes in the two CL Brener haplotypes. The rationale underlying
this strategy is that, because CL Brener is a recent hybrid between the TcII and TcIII DTUs (discrete typing units), it is likely
that polymorphic epitopes in pairs of alleles could also be polymorphic in the parental genotypes. We excluded sequences
that are also present in the Leishmania major, L. infantum, L. braziliensis and T. brucei genomes to minimize the chance of
cross-reactivity. A peptide array containing 150 peptides was covalently linked to a cellulose membrane, and the reactivity
of the peptides was tested using sera from C57BL/6 mice chronically infected with the Colombiana (TcI) and CL Brener (TcVI)
clones and Y (TcII) strain.
Findings and Conclusions: A total of 36 peptides were considered reactive, and the cross-reactivity among the strains is in
agreement with the evolutionary origin of the different T. cruzi DTUs. Four peptides were tested against a panel of chagasic
patients using ELISA. A conserved peptide showed 95.8% sensitivity, 88.5% specificity, and 92.7% accuracy for the
identification of T. cruzi in patients infected with different strains of the parasite. Therefore, this peptide, in association with
other T. cruzi antigens, may improve Chagas disease serodiagnosis. Together, three polymorphic epitopes were able to
discriminate between the three parasite strains used in this study and are thus potential targets for Chagas disease
serotyping.
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Introduction
Chagas disease, a zoonosis caused by the protozoan parasite
Trypanosoma cruzi, affects approximately 10 million people in the
Americas. Approximately 14,000 deaths occur annually, and
50,000–200,000 new cases are diagnosed each year [1]. During
the acute phase of infection, diagnosis is based on parasitological
methods [2]; however, in the chronic phase, such parasitological
approaches have a low sensitivity, between 50–65%, because of
low levels of parasitemia [3,4]. The chronic phase is also
characterized by a strong and persistent humoral immune
response, thus the measurement of IgG antibodies specific for
parasite antigens should be performed for diagnosis [5]. However,
serological methods from different laboratories have been
observed to be inconclusive or contradictory [6–8]. These
discrepancies are mainly related to technical errors and antigen
composition because crude or semi-purified protein extracts of
epimastigotes, a parasite stage not found in the mammalian host,
are generally used [6,9]. Moreover, false-positive results are
frequently observed because of the cross-reactivity of crude
preparations of T. cruzi antigens with sera from individuals
infected with Leishmania sp. and T. rangeli [10–12]. The use of
recombinant antigens and synthetic peptides as a substitute for
parasite lysates has increased reproducibility and, in addition, does
not require the maintenance and processing of live parasites
[13,14]. Despite recent advances in Chagas disease diagnostics, the
methods available still have limitations related to low specificity
and sensitivity [15,16]. Among the factors that compromise the
performance of diagnostic tests, the genetic variability of the
parasite is known to contribute to false-negative results in Chagas
disease serodiagnosis [17].
Epidemiological, biochemical, and molecular studies have
demonstrated that the T. cruzi taxon is extremely polymorphic
[18–21]. Recently, T. cruzi strains were reclassified into six DTUs
(discrete typing units) called TcI to TcVI [22], and there is much
speculation regarding whether this parasite variability could be
associated with different disease prognoses. Although T. cruzi
infection results in a broad spectrum of clinical forms as
indeterminate, cardiac, and digestive forms, the determinant
factors involved in the development of each clinical form have not
been elucidated, though it is likely that genetic factors of the host
and parasite are involved [23]. However, no study to date has
found an unequivocal association between the infecting parasite
DTU and the clinical forms of the disease. Nevertheless, this
hypothesis has not been discarded because correlations between
the geographic distribution profiles of different T. cruzi DTUs and
a higher frequency of specific clinical forms have been reported
[21]. Indeed, digestive manifestations are more common in the
central region of Brazil and the southern part of South America,
where infection by TcII, TcV, and TcVI predominates; in
contrast, such manifestations are rare in the northern part of
South America and in Central America, where infection caused by
TcI is more common [24].
Correlation studies between the parasite DTU and clinical
forms of Chagas disease are challenging because most of the
techniques require parasite isolation from patient blood or parasite
genotyping directly from infected tissues. Because many T. cruzi
populations are polyclonal, hemoculture may select sub-popula-
tions of parasites more adapted to in vitro growth conditions [25].
Moreover, because of different tissue tropisms of some T. cruzi
strains [26], in infections caused by polyclonal populations and/or
co-infections, the clones circulating in the patient blood may not
be the same as those found in tissue lesions. The current
methodologies to genotype the parasite from tissue biopsies are
laborious and expensive, thus limiting the number of samples that
can be analyzed. Within this context, a parasite typing method
based on the detection of strain-specific antibodies from patient
sera could resolve many of these problems. Thus far, there is only
one study that proposes the use of an antigen to discriminate
among T. cruzi DTUs [17]. This study is based on an antigen
named TSSA (trypomastigote small surface antigen), belonging to
the TcMUC III protein family, which can differentiate between
humans infected with TcI, TcIII, and TcIV and those infected
with TcII, TcV, and TcVI.
In the present study, we performed a genomic screen to identify
polymorphic and conserved linear B-cell epitopes in the predicted
proteome of the CL Brener T. cruzi strain in an attempt to identify
targets for the serotyping and serodiagnosis, respectively, of T.
cruzi-infected patients. The results were validated using sera from
experimentally infected mice and chagasic patients.
Materials and Methods
Ethics statement
The design and methodology of all experiments involving mice
were in accordance with the guidelines of COBEA (Brazilian
College of Animal Experimentation), strictly followed the Brazilian
law for ‘‘Procedures for the Scientific Use of Animals’’ (11.794/
2008), and were approved by the animal-care ethics committee of
the Federal University of Minas Gerais (protocol number 143/
2009).
The study protocol involving human samples from Bolivia was
approved by the ethics committees of the study hospital, A.B.
PRISMA, Johns Hopkins University and the U.S. Centers for
Disease Control and Prevention. All subjects provided written
informed consent before blood was collected. As for the Brazilian
patients, written informed consent was obtained from the
participants and was approved by the Ethics Committee of the
Author Summary
Serological tests are preferentially used for the diagnosis of
Chagas disease during the chronic phase because of the
low parasitemia and high anti-T. cruzi antibody titers.
However, contradictory or inconclusive results, mainly
related to the characteristics of the antigens used, are
often observed. Additionally, the factors influencing
variation in the clinical forms of Chagas disease have not
been elucidated, although it is likely that host and parasite
genetics are involved. Several studies attempting to
correlate the parasite strain with the clinical forms have
used hemoculture and/or PCR-based genotyping. Howev-
er, both techniques have limitations. Hemoculture requires
the isolation of parasites from patient blood and the
growth of these parasites in animals or in vitro culture,
thereby possibly selecting certain subpopulations. More-
over, the level of parasitemia in the chronic phase is very
low, hindering the detection of parasites. Additionally,
direct genotyping of parasites from infected tissues is an
invasive procedure that requires medical care and hinders
studies with a large number of samples. The goal of this
work was to identify conserved and polymorphic linear B-
cell epitopes of T. cruzi on a genome-wide scale for use in
the serodiagnosis and serotyping of Chagas disease using
ELISA. Development of a serotyping method based on the
detection of strain-specific antibodies may help to under-
stand the relationship between the infecting strain and
disease evolution.
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Federal University of Minas Gerais (UFMG), under protocol
number No. 312/06.
Mouse sera
Each experimental group was composed of six 2–4-week-old
C57BL/6 male mice. The mice were infected with 50 Colombiana
or 500 Y trypomastigotes. For the CL Brener clone, we used three
mouse groups infected with 50, 100, or 500 trypomastigotes.
Infection was confirmed by the observation of trypomastigote
forms in blood collected from the tail at seven days after
intraperitoneal inoculation. One additional group was infected
with 16105 T. rangeli trypomastigotes, and the infection was
confirmed by PCR [27]. Six un-infected mice were used as the
control group. The chronic phase of infection was confirmed after
approximately 3 months by negative parasitemia and the presence
of anti-parasite IgG (as tested against T. cruzi and T. rangeli crude
antigens) by ELISA [28]. Mouse blood was then obtained by
cardiac puncture; coagulation was performed at room temperature
for 30 minutes, and the serum was obtained after centrifugation at
40006g for 15 minutes.
Human sera
Blood samples from chagasic patients from Bolivia were
collected in a public hospital in Santa Cruz de la Sierra. DNA
was extracted from patient blood samples and parasite genotyping
was performed as previously described [29]. Infection by TcI
parasite lineage was confirmed for six samples (Supplementary
Figure S1). Samples from 10 chagasic patients previously
characterized to be infected with TcII [30] and 56 samples from
chagasic patients infected with untyped parasites collected from
Rio Grande do Norte State, Brazil, were also used. Samples from
14 patients infected with L. braziliensis and 14 patients with visceral
leishmaniasis both known to be un-infected with T. cruzi and the
sera from 24 un-infected humans were used as specificity and
negative controls, respectively.
Parasites
Epimastigotes of the Colombiana and CL Brener clones, and Y
strain of T. cruzi and T. rangeli SC-58 were maintained in a
logarithmic growth phase at 28uC in liver infusion tryptose (LIT)
medium supplemented with 10% fetal bovine serum, 100 mg/mL
streptomycin, and 100 units/mL penicillin [31]. A total of 16106
T. cruzi epimastigotes/mL were incubated in triatomine artificial
urine (TAU) medium for 2 hours at 28uC. L-proline (10 mM) was
added to the medium, and the metacyclic forms were obtained
after 72 hours at 28uC [32]. Trypomastigotes and amastigotes
were obtained from rhesus-monkey epithelial LLC-MK2 cells
infected with metacyclic forms cultured in RPMI medium
supplemented with 2% fetal bovine serum at 37uC and 5% CO2
[31]. Differentiation of T. rangeli epimastigotes to trypomastigotes
was induced with 106 parasites/mL in DMEM medium (pH 8) for
6 days at 28uC [33].
In silico prediction of linear B-cell epitopes
Linear B-cell epitopes were predicted for all the proteins of the
CL Brener genome release 4.1 [34] using the Bepipred 1.0
program with a cutoff of 1.3 [35]. The BepiPred program assigns a
score to each individual amino acid in a sequence, therefore only
amino acids with prediction Bepipred score $1.3 were considered
for the downstream analysis. Proteins encoded by the pair of Esmo
and Non-Esmo alleles were aligned using the CLUSTALW
program [36], and each pair of amino acids aligned received a
polymorphism score according to the following scale: 0 for
identical amino acids; 1 for different amino acids with similar
physical-chemical properties; 2 for a mismatch involving amino
acids with dissimilar physical-chemical properties; and 3 for a gap
position. A perl script based on a sliding window approach that
uses a fixed window size of 15 amino acids and an increment of
one amino acid identified all 15-mer subsequences in which each
individual amino acid has a bepipred score $1.3. Those peptides
with a polymorphism score above 6 (sum of the individual amino
acid polymorphism scores) and a mean BepiPred score $1.3 were
classified as polymorphic epitopes; those peptides identical
between the Esmo and Non-Esmo haplotypes and with a mean
BepiPred prediction score $1.3 were classified as conserved
epitopes. The selected peptides were compared with the predicted
proteins from the genomes of L. infantum, L. major, L. braziliensis,
and T. brucei (release 4.1) [37] using the BLASTp algorithm [38].
Peptides with at least 70% similarity along 70% of the length were
discarded. After elimination of peptides with potential cross-
reactivity with Leishmania and T. brucei, 50 Esmo-like peptides, 50
Non-esmo-like peptides and 50 peptides conserved with the
highest mean Bepipred score were selected.
Spot synthesis and immunoblotting
Peptides were synthesized on pre-activated cellulose membranes
according to the SPOT synthesis technique [39]. Briefly, Fmoc-
amino acids were activated with 0.05 mM HOBt and 0.1 mM
DIC and automatically spotted onto pre-activated cellulose
membranes using the MultiPep SPOT synthesizer (Intavis AG).
The non-binding sites of the membrane were blocked with 10%
acetic anhydride, and the Fmoc groups were removed with 25% 4-
methyl piperidine. These processes were repeated until peptide
chain formation was complete. After synthesis, side-chain
deprotection was performed by adding a 25:25:1.5:1 solution of
trifluoroacetic acid, dichloromethane, triisopropylsilane, and
water. The amino acid coupling and side-chain deprotection were
monitored by staining the membrane with 2% bromophenol blue.
The immunoblotting methodologies followed a previously de-
scribed protocol [39]. First, the membrane containing peptides
was blocked with 5% BSA and 4% sucrose in PBS overnight and
incubated with infected and control mouse sera diluted 1:5,000 in
blocking solution for 1 hour. After washing three times with PBS-
T (PBS; 0.1% Tween 20), the membrane was incubated with the
secondary HRP-conjugated anti-mouse IgG antibody (Sigma-
Aldrich) diluted 1:10,000 in blocking solution for 1 hour. After a
third wash, detection was performed using ECL Plus Western
blotting (GE Healthcare), following the manufacturer’s instruc-
tions, with the Gel Logic 1500 Imaging System (Kodak). The
densitometry measurements and analysis of each peptide were
performed using Image Master Platinum (GE), and the relative
intensity ratio (RI) cutoff for positivity was determined at 2.0.
Soluble peptide synthesis
The soluble peptides were synthesized in solid phase on a 30-
mmol scale using N-9-fluorenylmethoxycarbonyl [40] with PSSM8
equipment (Shimadzu). Briefly, Fmoc-amino acids were activated
with a 1:2 solution of HOBt and DIC. The active amino acids
were incorporated into Rink amide resin with a substitution degree
of 0.61. Fmoc deprotection was then performed using 25% 4-
methylpiperidine. These steps were repeated until the synthesis of
each peptide was complete. The peptides were deprotected and
released form the resin by treatment with a solution of 9.4%
trifluoroacetic acid, 2.4% water, and 0.1% triisopropylsilane. The
peptides were precipitated with cold diisopropyl ether and purified
by high-performance liquid chromatography (HPLC) on a C18
reverse-phase column using a gradient program of 0 to 25%
Strain-Specific T.cruzi B-Cell Epitopes
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acetonitrile. The peptides were obtained with 90% purity, as
confirmed by mass spectrometry using Autoflex Speed MALDI/
TOF equipment.
ELISA and affinity ELISA
Each well of flexible ELISA polyvinylchloride plates (BD
Falcon) was coated with 2 mg of soluble peptide. After blocking
with 5% BSA in PBS for 1 hour at 37uC, followed by three
washing steps with PBS containing 0.05% Tween 20 (PBS-T), the
plates were incubated with human or mouse serum (dilution
1:100). The plates were washed three times with PBS-T, and
secondary HRP-conjugated anti-human or anti-mouse IgG
antibody was added for 1 hour at 37uC, followed by four washes.
A solution containing 0.1 M citric acid, 0.2 M Na2PO4, 0.05%
OPD, and 0.1% H2O2 at pH 5.0 was used for detection; the
reaction was stopped with 4 N H2SO4, and the absorbance was
measured at 492 nm. The mean optical density value at 492 nm
plus three times the standard deviation of the negative serum was
used as the cutoff value. For affinity ELISA, 6 M urea was added
for 5 min at 37uC after incubation with the primary antibodies;
the remainder of the protocol was the same [41]. The results are
shown as an affinity index (AI) determined as the ratio between the
absorbance values of the samples treated and not treated with
urea. An AI value lower than 40% represented low-affinity
antibodies, between 41 and 70% was classified as intermediate
affinity and higher than 70% as high affinity.
DNA extraction and sequencing
Genomic DNA extraction was performed using the GFXTM
Genomic Blood DNA Purification kit (GE Healthcare) following
the manufacturer’s instructions. The DNA samples were quanti-
fied using a NanoDrop Spectrophotometer ND-1000 (Thermo
Scientific). The PCR products amplified with the primers listed in
Supplementary Table S1 were subjected to sequencing at both
ends using the ABI Prism 37306l DNA Analyzer (Applied
Biosystems) by Macrogen Inc (Korea).
RNA extraction and cDNA synthesis
Total RNA was isolated from 108 epimastigotes, 106 trypomas-
tigotes, and 108 LLC-MK2 cells infected with approximately 105
intracellular amastigotes of the Colombiana, Y, and CL Brener
strains using the NucleoSpin RNA II RNA extraction kit
(Macherey-Nagel) following the procedures described by the
manufacturer. RNA from 108 LLC-MK2 cells was also extracted
and used as a negative control. The concentration and purity of
the RNA samples were measured with a NanoDrop Spectropho-
tometer ND-1000 (Thermo Scientific). cDNA was synthesized
using 10 ng of total RNA and the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) using
random hexamer primers according to the manufacturer’s
instructions.
Real-time PCR
Specific primers for each Esmo and Non-Esmo allele were
designed, and the primer specificity was verified by electronic PCR
using the entire parasite genome as a template. The primers used
are listed in the Supplementary Table S2. Real-time PCR
reactions were performed in an ABI 7500 sequence detection
system (Applied Biosystems). The reactions were prepared in
triplicate and contained 1 mM forward and reverse primers,
SYBR Green Master Mix (Applied Biosystems), and 20 ng of
cDNA. Standard curves were prepared for each experiment for
each pair of primers using serially diluted T. cruzi CL Brener
genomic DNA to calculate the relative quantity (Rq) values for
each sample. qRT-PCRs for the constitutively expressed GAPDH
gene were performed to normalize the expression of the specific
alleles.
Statistical analysis
All statistical analyses were performed using Graph Prism 5.0
software. First, the normal distribution of data was evaluated by
the Kolmogorov-Smirnov test; because all they showed a Gaussian
profile, an unpaired t test was used for the comparative analysis
between the two sets of data, and an ANOVA was used for three
or more experimental groups. P-values lower than 0.05 were
considered statistically significant. The sensitivity, specificity, and
accuracy of the peptides were also calculated for the human
samples. The sensitivity is represented by Se=TP/(TP+FN),
where TP (true positive) is the number of sera from individuals
infected with T. cruzi above the cutoff value and FN (false negative)
is the number of sera from infected individuals below the cutoff for
the conserved peptide. For the polymorphic peptides, TP was
defined as the number of sera from individuals infected with a
specific strain above the cutoff value, and FN is the number of
these sera below the cutoff for polymorphic peptides. The
specificity is represented by Sp=TN/(TN+FP), where TN (true
negative) is the number of sera from individuals infected with L.
braziliensis or un-infected individuals below the cutoff and FP (false
positive) is the number of sera from these samples with reactivity
the for conserved peptide. For the polymorphic peptides, TN was
defined as the number of sera from individuals infected with a
non-specific strain or L. braziliensis and uninfected individuals
below the cutoff, and FP is the number of sera from these samples
with reactivity. The accuracy is calculated as Ac= (TP+TN)/
(TP+TN+FP+FN).
Results
Epitope prediction using the T. cruzi CL Brener proteome
and immunoblotting screening
We performed B-cell epitope prediction for 3,983 proteins
derived from pair of alleles of CL Brener genome. We decided to
restrict our analysis to this dataset because the CL Brener clone is
a recent hybrid between the TcII and TcIII DTUs and evidence
suggests that the latter is an ancient hybrid between TcI and TcII
[42]. Therefore, it is likely that polymorphic epitopes in the pairs
of alleles of CL Brener could also be polymorphic for its parental
genotypes and other T. cruzi strains. In the CL Brener hybrid
diploid genome, it is possible to identify two haplotypes: ‘‘Esmo’’,
which is more similar to TcII; and ‘‘Non-Esmo’’, which is more
similar to TcIII [34]. A total of 1,488 predicted epitopes were
classified as conserved between the two haplotypes, and 428 were
classified as polymorphic. We next excluded epitopes also present
in Leishmania major, L. infantum, L. braziliensis and T. brucei to
minimize the chance of cross-reactivity, because these parasites
share many antigens with T. cruzi [10,12,16], thus reducing the
number of conserved and polymorphic epitopes to 1,086 and 242,
respectively.
A total of 50 conserved, 50 polymorphic Esmo-specific, and 50
polymorphic Non-Esmo-specific peptides with high epitope
prediction scores were selected for the construction of peptide
arrays. The reactivity of the peptides was tested using a pool of
sera from six C57BL/6 mice chronically infected with Colombi-
ana (TcI), Y (TcII), or CL Brener (TcVI) strains and un-infected
mice as the control group (Figure 1). The quantification of the
reactivity was performed by densitometric analysis (Supplementary
Table S3). A peptide was considered reactive and antigenically
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conserved if its intensity signal with all T. cruzi strains was two
times higher than its signal with the sera from un-infected mice. A
peptide was considered reactive and antigenically polymorphic if
its intensity signal with a specific strain was two times higher than
the values with the other two strains and the un-infected mice. A
total of 36 peptides were considered reactive with at least one
Figure 1. Immunoscreening of peptide arrays with sera from mice infected with different T. cruzi strains. (A) Sera from un-infected mice;
sera from mice infected with Colombiana (TcI) (B), Y (TcII) (C), or CL Brener (TcVI) (D). (E) Venn diagram showing the specific and shared epitopes
among T. cruzi strains.
doi:10.1371/journal.pntd.0002524.g001
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strain (Figure 1E). A conserved peptide with the highest reactivity
with all T. cruzi strains (C6_30_cons) and three polymorphic
peptides specific for Colombiana (A6_30_col), Y (B2_30_y), and
CL Brener (B9_30_cl) were selected for soluble synthesis, and their
reactivity was validated by ELISA.
Epitope validation with ELISA and affinity ELISA
Because immunoblotting assays are semi-quantitative tech-
niques, we validated the results with quantitative ELISA and
affinity ELISA assays using individual sera from six C57BL/6
mice chronically infected with the Colombiana (TcI), Y (TcII), or
CL Brener (TcVI) strains and the un-infected mice as a control
group. For the conserved peptide C6_30_cons, no significant
difference in the reactivity among the sera from animals infected
with different T. cruzi strains was observed (Figure 2A). The sera
from mice infected with the Colombiana strain had a higher
antibody titer against the A6_30_col peptide compared to the sera
from mice infected with the Y strain. More importantly, the
affinity antibodies discriminated Colombiana infection from those
caused by the other two strains (Figure 2B). An expected
recognition profile was also observed for the peptide B2_30_y
(Figure 2C): sera from mice infected with the Y strain had a
significantly higher antibody titer than those from mice infected
with Colombiana, and the highest affinity antibodies generated by
the Y strain discriminated its infection from those caused by
Colombiana and CL Brener. With regard to peptide B9_30_cl,
conventional ELISA was able to discriminate CL Brener infection
from that caused by Y and Colombiana (Figure 2D).
Because the infection caused by different T. cruzi strains has
specific evolution and mortality rates in a mouse model [43], we
infected mice with a distinct parasite inoculum for each strain to
reach the chronic phase when the sera were collected. Thus, to
evaluate whether the differences in reactivity observed in the
ELISA experiments were dependent on the inoculum, we tested
the reactivity of sera from mice infected with 50, 100, or 500 CL
Brener trypomastigotes (Supplementary Figure S2). There was no
significant variation among the different CL Brener inocula,
suggesting that the antigenic variability among the parasite strains
is the main factor responsible for the distinct recognition profile of
the peptides tested in the ELISA experiments. The evaluation of
cross-reactivity with sera from mice infected with T. rangeli and
from Leishmaniasis patients demonstrated that the peptides are T.
cruzi specific (Supplementary Figures S3 and S4).
Prediction of specific epitope reactivity with different T.
cruzi DTUs
We next analyzed the polymorphisms of the epitopes identified
in this study and predicted their reactivity with sera from
individuals infected with T. cruzi strains representative of each
DTU (TcI to TcVI). To this end, we first subjected the peptide
sequences to an AlaScan analysis [44] to identify the amino acid
residues critical to antibody binding. We found that the pattern
GXXXXMRQNE in the carboxy-terminal region of conserved
peptide C6_30_cons is important for the interaction with the
antibodies generated in infection caused by the three T. cruzi
strains (Figures 3A, B, and C). As for the polymorphic epitopes, the
patterns PPXDXSLXXP in peptide A6_30_col (Figure 3D),
QPQPXPQXXXQP in B2_30_y (Figure 3E), and DEXXXXG
in B9_30_cl (Figure 3F) are critical for binding with the antibodies
generated by Colombiana, Y, and CL Brener infections,
respectively.
We then sequenced the genomic DNA encoding these four
epitopes in strains representative of the six T. cruzi DTUs to
predict whether the peptides would be recognized in infections
caused by different parasite DTUs. It is expected that a peptide
would be recognized in infections caused by a specific strain if the
amino acid residues critical for antibody recognition are encoded
by its genome. Based on this criterion, we predicted that conserved
peptide C6_30 would be able to identify infection caused by four
of the six T. cruzi DTUs (Figure 4A), whereas peptides A6_30_col
and B2_30_y are expected to identify infections caused only by
TcI and TcVI (Figure 4B) and TcII and TcVI (Figure 4C),
respectively. Interestingly, the A6_30_col and B2_30_y epitopes
are identical to the Non-Esmo- and Esmo-like CL Brener
haplotypes, respectively, reinforcing the hypothesis that the nature
of the CL Brener hybrid may have contributions of both the TcI
and TcII genomes. B9_30_cl is predicted to identify patients
infected with TcIII or TcVI (Figure 4D).
Epitope expression at different parasite stages and
strains
Although all peptides are derived from the CL Brener genome,
the sera from mice infected with this strain had lower antibody
affinities for the A6_30_col and B2_30_y peptides than did the
sera from mice infected with the Colombiana or Y strain (Figure 2).
Because CL Brener is a hybrid strain [34,42,45], the polymorphic
epitopes encoded by its pairs of alleles may have distinct expression
levels that could explain the differences in their reactivity. To
investigate this further, we designed allele-specific primers for the
genes that encode the epitopes to evaluate their expression levels in
the trypomastigote and amastigote forms, the parasite stages found
in mammalian hosts (Figure 5). As expected based on the T. cruzi
phylogeny [46], Y expressed only the Esmo-like variants, and
Colombiana expressed only the Non-Esmo variants, except for the
B9_30 transcript. CL Brener expressed both alleles of all genes,
except for the B9_30 transcript. The conserved peptide was
expressed by both the Esmo and Non-Esmo haplotypes of CL
Brener (Figure 5A). The polymorphic Non-Esmo peptide
A6_30_col was expressed by the Colombiana and CL Brener
strains (Figure 5B), and CL Brener also expressed the Esmo-like
allele for this peptide. The opposite profile was observed for the
polymorphic Esmo B2_30_y peptide, whereby only the Y and CL
Brener strains expressed the Esmo-like allele and CL Brener also
expressed the Non-Esmo allele of this peptide (Figure 5C). CL
Brener only expressed the Esmo-like variant of the B9_30_CL
epitope, and its level of expression was approximately 5 times
higher than in the Y strain (Figure 5D).
Potential use of epitopes for human serodiagnosis and
serotyping
All previous results were based on a mouse model because the
amount of the inoculum, infective strain, and time of infection can
be adequately controlled. To test the potential application of these
peptides for serodiagnosis and serotyping of human infection, we
performed ELISA experiments with sera from chagasic patients
with parasites genotyped as TcI or TcII, and healthy individuals.
The conserved peptide C6_30_cons showed 95.8% sensitivity,
88.5% specificity, and 92.7% accuracy for the identification of
chagasic patients, and no significant differences in the reactivity of
sera from patients infected with TcI or TcII was observed
(Figure 6). As expected, peptide A6_30_col showed much higher
reactivity with the sera from patients infected with TcI (Figure 7A),
with 100% sensitivity, 91.9% specificity, and 92.6% accuracy;
peptide B2_30_y identified most of the individuals infected with
TcII (Figure 7B), with 80% sensitivity, 94.8% specificity, and
92.6% accuracy. Additionally, none of the sera from patients
infected with TcI recognized the B2_30_y peptide, and peptide
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Figure 2. Reactivity and affinity of sera from T. cruzi-infected mice against conserved and polymorphic epitopes. (A) Peptide
C6_30_cons. (B) Peptide A6_30_col. (C) Peptide B2_30_y. (D) Peptide B9_30_cl. The dotted line represents the cutoff value. The solid gray line
represents the mean values. C-, un-infected mice. Colombiana (TcI), mice infected with the Colombiana strain. Y (TcII), mice infected with the Y strain.
CL Brener (TcVI), mice infected with the CL Brener strain. *p,0.05 and **p,0.005.
doi:10.1371/journal.pntd.0002524.g002
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B9_30_cl showed a low reactivity with both TcI and TcII
(Figure 7C). All peptides were also T. cruzi specific because the
majority of the sera from the patients infected with L. braziliensis
were non-reactive (Supplementary Figure S4).
Discussion
Despite efforts to identify new targets for the immunodiagnosis
of Chagas disease, the impressive genetic variability of T. cruzi
strains has imposed serious limitations on the development of high-
sensitivity methods [47–50]. Additionally, serological cross-reac-
tivity with Leishmania and T. rangeli infections [11,12,16] compro-
mises the specificity of Chagas disease diagnosis. Therefore, the
identification of new T. cruzi-specific antigens conserved among
the parasite strains has been recognized as an important research
area for Chagas disease diagnosis and control [47]. The
polymorphic nature of T. cruzi isolates, on the other hand, opens
new avenues for the development of serotyping methodologies to
identify the parasite DTU causing infection based on a serological
survey. For instance, this would allow large-scale epidemiological
studies aimed at correlating the strain causing the infection with
the clinical forms of Chagas disease, an open question that has
been hampered by the limited number of samples that can be
analyzed by the current genotyping methodologies [48]. To the
best of our knowledge, only one study has identified a polymorphic
epitope among the T. cruzi DTUs [49]. This marker is an
immunodominant B-cell epitope of TSSA (trypomastigote small
surface antigen), a representative of the TcMUC III gene family.
The TSSA-I and TSSA-II isoforms serologically discriminate
between animals infected with T. cruzi I from those infected with
T. cruzi II, according to the previous DTU classification (TcII-VI
in the current classification), respectively. In a serological survey of
chagasic patients from Argentina, Brazil, and Chile, anti-TSSA
antibodies recognized only the TSSA-II isoform, suggesting that
the TcII-VI DTUs are the cause of Chagas disease in those
regions. In a more recent study, however, this same research group
analyzed the diversity of the TSSA gene in several representatives
of each of the six T. cruzi DTUs and found a complex pattern of
sequence polymorphism. Based on their analysis, the epitope
considered to be specific for TcII-VI was shown to identify the
TcII, V, and VI DTUs. In addition, the peptide previously
described as TcI specific shares key features with TcIII and IV.
Therefore, there is no T. cruzi DTU-specific serological marker
identified thus far.
The goal of this work was to identify conserved and
polymorphic linear B-cell epitopes of T. cruzi for Chagas disease
serodiagnosis and serotyping using ELISA. This technique was
selected because it is a quantitative assay and easily automated,
thus allowing the analysis of a large number of samples. In recent
years, synthetic peptides used as antigens have shown high
sensitivity and specificity in diagnostic tests [50]. Peptides have
several advantages over chemically purified or recombinant
antigens because their production does not involve the manipu-
lation of living organisms and can be obtained with a high level of
purity [51]. Recently, the use of peptide arrays has allowed the
immunoscreening of a large number of epitope candidates [39].
Figure 3. Mapping of antibody binding sites on the conserved and polymorphic epitopes by Ala-Scan. Reactivity of peptide
C6_30_cons against the sera from mice infected with Colombiana (A), Y (B), and CL Brener (C). Reactivity of peptide A6_30_col against the sera from
mice infected with the Colombiana clone (D). Reactivity of peptide B2_30_y against the sera from mice infected with the Y strain (E). Reactivity of
peptide B9_30_cl against the sera from mice infected with the CL Brener clone (F). 1, original peptide. RI, relative intensity calculated by the ratio
between the reactivity of the peptide with a specific amino acid substitution and the original peptide. The dotted line indicates half of the intensity
value obtained with the original peptide. The red letters represent amino acid substitutions that reduce the reactivity to at least half of the value
obtained with the original peptide. The blue squares show the conserved amino acids critical for antibody binding with the sera from mice infected
with different T. cruzi strains.
doi:10.1371/journal.pntd.0002524.g003
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Thus, an approach based on a synthetic peptide array was chosen
to screen of a large number of potential antigens by immunoblot-
ting, followed by ELISA validation.
Initially, we screened the CL Brener genome to predict epitopes
that are polymorphic and conserved between the Esmo and Non-
Esmo haplotypes. The rationale underlying this strategy is that,
because the CL Brener strain is a recent hybrid between the TcII
and TcIII DTUs and there is evidence suggesting that the latter is
an ancient hybrid between TcI and TcII [46], it is likely that the
polymorphic epitopes between the CL Brener alleles would also be
polymorphic among distinct T. cruzi strains. The Colombiana
(TcI) and CL Brener (TcVI) clones and Y (TcII) strain were
selected for this study to evaluate the degree of polymorphism of
epitopes in TcII, a direct representative of one CL Brener parental
DTU, and TcI, a more distant DTU of CL Brener, along with CL
Brener.
The immunoscreening of 150 high-scoring peptides resulted in
the identification of 36 novel epitopes, indicating that our
computational approach for the prediction and prioritization of
epitope candidates was successful. Our rate of success (24%) was
slightly higher than previously described (19.5%) for T. cruzi using
a similar validation approach [50]. We found that only 11% (4/36)
of the reactive peptides are shared among the three parasite
strains (Figure 1E), highlighting the problem with identifying
Figure 4. Reactivity prediction of epitopes based on the sequences encoding the identified peptides in different T. cruzi strains. (A)
Peptide C6_30_cons. (B) Peptide A6_30_col. (C) Peptide B2_30_y. (D) Peptide B9_30_cl. The bold sequences represent the synthetic peptide tested.
The red letters represent key amino acids for antibody binding.
doi:10.1371/journal.pntd.0002524.g004
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high-sensitivity antigens for the serodiagnosis of Chagas disease
due to the high degree of T. cruzi polymorphism. One of the
conserved epitopes identified in this study, peptide C6_30_cons,
has proven to be a new conserved T. cruzi antigen with a potential
application in Chagas disease serodiagnosis (Figures 2A, 6A, S2,
and S3).
Together, the three polymorphic epitopes were able to
discriminate among infections caused by the three different T.
cruzi strains included in this study and, thus, have the potential to
be used for the serotyping of infections caused by this parasite.
ELISA experiments using human sera confirmed the predictive
reactivity of A6_30_col and B2_30_y (Figure 6). A6_30_col was
able to identify 100% of the patients infected with TcI. As
expected, the serum samples obtained from Brazilian patients
known to be infected with TcII were reactive only with the C6_30
conserved and B2_30_y peptides. These results confirm the
potential use of this peptide set for Chagas disease serotyping.
The peptide A6_30_col and B9_30_cl are derived from RNA
binding proteins and RNA polymerase III, respectively (Supple-
mentary Table S3). Both are predicted to have an intracellular
localization. Indeed, humoral response against intracellular
antigens is quite common in trypanosomatids as shown by the
work described by da Rocha et al., 2002 [52] that performed
immunoscreening of an amastigote cDNA library using sera from
chagasic patients. About 70% of the amastigote antigens identified
in this study is derived from intracellular parasite proteins. Similar
to Leishmania infection, it is postulated that during T. cruzi infection
a proportion of trypomastigotes/amastigotes cells are destroyed,
thus releasing substantial amounts of multicomponent complexes
containing intracellular antigens [53]. This reactivity could be the
result of high abundance of these antigens as circulating complexes
during the parasite infection due to high and constant expression
of nuclear and house-keeping genes; higher stability due to
formation of nucleoprotein particles more resistant to degradation;
and their increased capacity to be processed by antigen-presenting
cells because multicomponent particles are taken into the cell more
efficiently than soluble antigens [54].
It is worth noting that the conserved and polymorphic epitopes
identified in this study encompass repetitive regions. Interestingly,
two of these peptides have proline-rich regions (Figure 4) that may
be involved in protein-protein interactions in prokaryotes [55] and
eukaryotes [56]. It has been demonstrated that the overall
immunogenicity of proteins harboring tandem repeats is increased,
as is the antigenicity of epitopes contained within repetitive units
[52,57]. Therefore, one expects that repeats receive a high B-cell
epitope prediction score. Furthermore, the polymorphic epitopes
containing repeats were top ranked for an additional reason: our
polymorphic scale applied to the CL Brener pair of alleles
attributes the highest score to a gap position in the alignment, a
situation always present when the contraction or expansion of a
Figure 5. Expression levels of allele-specific genes encoding the identified conserved and polymorphic peptides. (A) Peptide
C6_30_cons. (B) Peptide A6_30_col. (C) Peptide B2_30_y. (D) Peptide B9_30_cl. INDEX was calculated by the copy number from the mRNA level of
each gene normalized by the GAPDH mRNA level. C-, negative control. T, trypomastigote. A, amastigote. E, epimastigote. The alleles were classified
based on the annotation of the hybrid CL Brener genome.
doi:10.1371/journal.pntd.0002524.g005
Figure 6. Reactivity of sera from humans infected with T. cruzi
against the conserved peptide C6_30_cons. The dotted line
represents the cutoff value. The solid gray line represents the mean
values. C-, uninfected human. TcI, Chagasic patients infected with TcI
DTU. TcII, Chagasic patients infected with the TcII DTU. Untyped,
Chagasic patients infected with untyped parasites.
doi:10.1371/journal.pntd.0002524.g006
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repetitive region occurs in one sequence but not in another. This
criterion was used because it is well known that repetitive
sequences evolve faster than other regions of the genome [58],
hence it is expect that they display a high level of polymorphism
among distinct parasite strains. Additionally, because it is known
that the number of repetitive antigenic motifs may affect antibody
binding affinity [59], we hypothesized that polymorphic repetitive
epitopes would be differentially recognized by the sera of animals
and human infected with distinct parasite DTUs, an assumption
that was reinforced by our results.
The cross-reactivity of the epitopes among the sera from mice
infected with distinct parasite strains is in agreement with an origin
hypothesis of the different T. cruzi DTUs. In two-way comparisons,
the CL Brener and Y strains, the two more phylogenetically
related strains, shared a higher number of epitopes (4) compared
to Y and Colombiana (1), whereas CL Brener and Colombiana
did not share any epitope (Figure 1E).
Interestingly, despite the fact that all of the peptides are derived
from the CL Brener genome, a smaller number of epitopes were
identified in this strain compared with Y and Colombiana
(Figure 1E). We speculate that the co-expression of alleles that
encode the polymorphic epitopes in CL Brener may affect the titer
of the antibody and/or its affinity for the variant epitopes. For
example, the pattern of expression and the reactivity of the
polymorphic peptides A6_30_col and B2_30_y (Figures 4B, 4C,
5B, and 5C) suggest that the co-expression of polymorphic
epitopes in CL Brener could induce low-affinity antibodies. A
similar phenomenon has been described for the polymorphic T.
cruzi trans-sialidase (TS) multigene family, whereby TS displays a
network of B-cell cross-reactive and polymorphic epitopes that
delays the generation of high-affinity neutralizing antibodies and
hamper an effective elicitation of a humoral response against these
proteins [60]. Whether this is a more general adaptive immune
evasion strategy that affects antibody affinity maturation, partic-
ularly in the case of hybrid strains, remains to be investigated.
Altogether, the results demonstrated that peptide C6_30_cons is
a new T. cruzi antigen conserved in the majority of DTUs of this
parasite. Using this peptide, in association with other T. cruzi
antigens, may improve the serodiagnosis of Chagas disease. The
three polymorphic epitopes identified were able to discriminate
among infections caused by the three different T. cruzi strains
included in this study and, thus, have the potential to be used for
the serotyping of infections caused by this parasite. This is the first
study on the genomic scale to identify DTU-specific antigens. The
genome sequencing of other T. cruzi strains will help identify new
strain-specific and conserved epitopes and increase the number of
antigen candidates for Chagas disease serodiagnosis and serotyp-
ing. The development of a robust panel of strain-specific epitopes
may allow large-scale epidemiological studies aimed at correlating
the infective strain with the variability in clinical outcomes
observed in chagasic patients.
Supporting Information
Figure S1 Genotyping of T. cruzi isolates infecting
chagasic patients from Bolivia. DNA extracted from blood
of chagasic patients was amplified using primers specific to the T.
cruzi mitochondrial COII gene followed by digestion with the AluI
restriction enzyme, as previously described (33), and separation by
electrophoresis in 8% polyacrylamide gel. DNA bands were
visualized by silver staining. MW, molecular weight; C-, negative
control; 1, Genomic DNA of Colombiana clone (TcI); 2, Genomic
DNA of Y strain (TcII); 3, Genomic DNA of CL Brener clone
(TcVI); 4–9, DNA extracted from blood of chagasic patients. DNA
fragments of 264-, 212- and 294-pb characterize TcI, TcII and
TcIII-TcVI DTUs, respectively (33).
(TIFF)
Figure S2 ELISA with the sera from mice infected with
different CL Brener strain inocula against conserved
and polymorphic peptides. (A) Peptide C6_30_cons. (B)
Peptide A6_30_col. (C) Peptide B2_30_y. (D) Peptide B9_30_cl.
The dotted line represents the cutoff value. The solid gray line
represents the mean values. C-, uninfected mice. CL Brener 50,
mice infected with 50 trypomastigotes of the CL Brener. CL
Figure 7. ELISA with sera from humans infected with TcI and
TcII T. cruzi DTUs against the polymorphic peptides. (A) Peptide
A6_30_col. (B) Peptide B2_30_y. (C) Peptide B9_30_cl. The dotted line
represents the cutoff value. The solid gray line represents the mean
values. C-, uninfected human. TcI, Chagasic patients infected with TcI
DTU. TcII, Chagasic patients infected with the TcII DTU. ***p,0.001.
doi:10.1371/journal.pntd.0002524.g007
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Brener 100, mice infected with 100 trypomastigotes of the CL
Brener. CL Brener 1000, mice infected with 1000 trypomastigotes
of the CL Brener.
(TIFF)
Figure S3 Cross-reactivity evaluation of conserved and
polymorphic peptides against the sera from mice
infected with T. rangeli. (A) Peptide C6_30_cons. (B) Peptide
A6_30_col. (C) Peptide B2_30_y. (D) Peptide B9_30_cl. The
dotted line represents the cutoff value. The solid gray line
represents the mean values. C-, uninfected mice. T. rangeli, mice
infected with T. rangeli.
(TIFF)
Figure S4 Cross-reactivity of conserved and polymor-
phic peptides against sera of patients with cutaneous
and visceral leishmaniasis. (A) Peptide C6_30_cons. (B)
Peptide A6_30_col. (C) Peptide B2_30_y. (D) Peptide B9_30_cl.
The dotted line represents the cutoff value. The solid gray line
represents the mean values. C-, uninfected humans. CL, patients with
cutaneous leishmaniasis. VL, patients with visceral leishmaniasis.
(TIFF)
Table S1 List of primers used to amplify the sequences
encoding the epitopes.
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time RT-PCR analysis.
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